Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01208012|
Recruitment Status : Completed
First Posted : September 23, 2010
Last Update Posted : March 15, 2011
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Drug: Victoza®||Phase 4|
Type 2 Diabetes Mellitus (DM) is associated with increased cardiovascular risk and the majority of type 2 diabetic patients die due to the vascular complications of Diabetes Mellitus. In type 2 diabetic patients, an early marker in the biogenesis of atherosclerosis and cardiovascular disease is the occurrence of endothelial dysfunction with subsequent deterioration in micro- and macrovascular blood flow and tissue supply. Also several mechanistic pathways linking Diabetes Mellitus with endothelial dysfunction and cardiovascular complications are postulated. Recent studies aimed to investigate the vasoprotective effect of strict glycaemic control using conventional treatment algorithms failed to reduce cardiovascular risk in patients with Diabetes Mellitus type 2. Numerous pharmacological drugs are available to reduce blood glucose levels in type 2 diabetic patients. Beside comparable glucose lowering efficacy, some of them evolve limited or even adverse effects on vascular function and cardiovascular risk. Therefore, ideally new treatments in Diabetes Mellitus type 2 provide more than just reducing blood glucose values. Future treatments in type 2 Diabetes Mellitus will be judged on their potency to affect the cardiovascular risk profile in patients with Diabetes Mellitus type 2.
Liraglutide is a Glucagon-like peptide-1 (GLP-1) analogue shown to be effective in the treatment of type 2 Diabetes Mellitus. Liraglutide was shown to improve blood glucose levels not only by stimulating insulin secretion from the β cell, but also by improving the conversion of intact proinsulin into insulin and C-peptide in the granula of the β cell. While in rodents, GLP-1 and its analogues showed an increase in β cell regeneration and an inhibitory effect on β cell apoptosis, the effect of GLP-1 analogues on β cell mass in humans is less clear. Beyond its effects on β cells, Liraglutide and other GLP1 analogues were shown to suppress the glucagon release from α cells and to evolve a supportive effect on weight reduction by central and probably peripheral effects.
Beside these effects of GLP-1-analogues on β cell physiology and glucose metabolism, recent studies suggested several pleiotrophic effects of GLP-1 treatment which go beyond glycaemic control. Receptors for GLP-1 have been located in myocardial and endothelial cells, and GLP-1 supplementation was found to improve myocardial and endothelial function in diabetic and in non-diabetic subjects. In endothelial cells, isolated from human coronary arteries, GLP-1 rapidly activates endothelial nitric oxide synthase (eNOS) and stimulates nitric oxide (NO) production, promotes cell proliferation and inhibits glucolipoapoptosis. In addition, in transformed vascular endothelial cells, GLP-1 protects endothelial dysfunction incurred by tumor necrosis factor-α (TNF-α) through the modulation of the expression of vascular adhesion molecules and plasminogen activator inhibitor-1 (PAI-1). Chronic administration of GLP-1 analogues is associated with a significant reduction in blood pressure. Therefore it seems conceivable, that in patients with Diabetes Mellitus type 2, treatment with the GLP-1 analog Liraglutide might improve the cardiovascular risk profile beyond glucose control by stimulating endothelial NO release and by improving endothelial function.
The goal of our study is to investigate the vascular and endothelial effects of adding Liraglutide treatment to type 2 diabetic patients previously treated with Metformin.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||November 2010|
No Intervention: Metformin
Patients taking Metformin at individual dose
Experimental: Metformin and Liraglutide
Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Other Name: Victoza®, Liraglutide
- The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Retinal capillary blood flow will be assessed using scanner laser doppler flowmetry.
- Central vascular elasticity [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Central arterial elasticity will be measured by Pulse wave velocity.
- Skin endothelial function and Skin oxygenation [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Microvascular skin blood flow and postcapillary tissue oxygenation (sO2)will be measured.
- Blood glucose control [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Fasting plasma glucose will be measured.
- Blood glucose control [ Time Frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline ]HbA1c will be maesured.
- Change of biomarkers of sub-clinical inflammation and cardiovascular risk [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Biomarkers PAI-1, hsCRP, VCAM, E-selectin and ADMA will be measured.
- Change of biomarker of heart failure [ Time Frame: timepoint 0 and after 6 and 12 weeks ]NT-pro BNP will be measured.
- Insulin/ intact Proinsulin ratio, C-peptide [ Time Frame: timepoint 0 and after 6 and 12 weeks ]Insulin Intact Proinsulin and C-peptide will be maesured.
- Change of body weight [ Time Frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline ]Body weight will be measured.
- Safety evaluation [ Time Frame: up to 2 weeks before baseline and after 12 weeks post baseline ]
The safety evaluation includes:
- Metabolic parameters indicating hepatic function (ALAT, ASAT, γ-GT)
- Blood analysis (Alkaline Phosphatase, Blood cell count)
- Change in pancreas function (Amylase, Lipase)
- Change in renal function (Creatinine, Potassium)
- Change in thyroid function (Calcitonin)
- Vital signs (Blood Pressure, Radial Pulse, ECG)
- β-HCG (only female patients of childbearing potential)
- Adverse Events
- Adverse Drug Reactions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01208012
|IKFE Institute for Clinical Research and Development|
|Mainz, Germany, 55116|
|Principal Investigator:||Thomas Forst, Prof. Dr.||Ikfe GmbH|